We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SGMO market cap is 101.12M. The company's latest EPS is USD -0.4200 and P/E is -1.05.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 481k | 356k | 49.41M | 7.55M | 6.44M |
| Operating Income | -47.18M | -35.91M | 10.63M | -28.19M | -29.63M |
| Net Income | -49.09M | -36.13M | 10.67M | -23.4M | -30.6M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 118.19M | 110.7M | 111.3M | 176.23M | 57.8M |
| Operating Income | -129.55M | -183.34M | -201.28M | -208.48M | -98.45M |
| Net Income | -121M | -178.29M | -192.28M | -257.83M | -97.94M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 128.96M | 93.01M | 111.26M | 101.64M | 86.17M |
| Total Liabilities | 72.26M | 69.32M | 72.13M | 78.87M | 81.26M |
| Total Equity | 56.7M | 23.69M | 39.13M | 22.77M | 4.91M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 938.55M | 721.92M | 562.51M | 165.32M | 101.64M |
| Total Liabilities | 441.18M | 346.58M | 267.55M | 82.43M | 78.87M |
| Total Equity | 497.37M | 375.34M | 294.96M | 82.89M | 22.77M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -48.66M | -75.55M | -63.79M | -67.14M | -26.15M |
| Investing | 35.84M | 35.97M | 36.2M | 37.52M | N/A |
| Financing | 22.12M | 21.59M | 21.39M | 28.38M | 8.13M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 169.88M | -233.25M | -223.63M | -224.84M | -67.14M |
| Investing | -271.63M | 248.2M | 59.29M | 153.53M | 37.52M |
| Financing | 153.1M | 32.86M | 84.66M | 14.59M | 28.38M |
| Market Cap | 101.12M |
| Price to Earnings Ratio | -1.05 |
| Price to Sales Ratio | 1.77 |
| Price to Cash Ratio | 2.45 |
| Price to Book Ratio | 4.51 |
| Dividend Yield | - |
| Shares Outstanding | 233.17M |
| Average Volume (1 week) | 3.21M |
| Average Volume (1 Month) | 4.25M |
| 52 Week Change | -2.47% |
| 52 Week High | 3.179 |
| 52 Week Low | 0.304 |
| Spread (Intraday) | 0 (0.85%) |
| Company Name | Sangamo Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.sangamo.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
